Can people on dialysis take Entresto (sacubitril/valsartan)?
Entresto is a prescription heart-failure medicine (sacubitril/valsartan). For people on dialysis, the key issue is that both sacubitril and valsartan can be affected by reduced kidney function, and the medicine’s dosing and safety may need adjustment.
In practice, clinicians typically consider dialysis patients on a case-by-case basis, weighing the potential heart-failure benefit against risks such as low blood pressure and kidney-related adverse effects. The most reliable source for exact dialysis dosing and warnings is the drug’s prescribing information.
What happens to Entresto when kidneys don’t work (including dialysis)?
Dialysis patients have advanced kidney failure, which changes how drugs are cleared from the body. When clearance is reduced, exposure to some components of therapy can rise, increasing the chance of side effects.
The main safety concerns clinicians watch in dialysis patients are:
Low blood pressure (hypotension), especially after starting or increasing dose.
Higher risk of electrolyte problems and kidney-related complications.
Drug intolerance symptoms that can mimic worsening heart failure.
Because dialysis can remove some drugs while not removing others, the “dialysis effect” matters for each medicine.
Does dialysis remove Entresto from the blood?
Whether dialysis meaningfully clears Entresto (or its active metabolites) depends on the drug’s chemistry and how it interacts with dialysis filters. If the drug (or active components) are not efficiently dialyzed, the medicine may behave more like a non-dialyzable drug, meaning timing doses around dialysis sessions may not change exposure much.
This is why dialysis-specific guidance in the prescribing information is important for safe dosing.
What side effects are dialysis patients most likely to experience on Entresto?
Patients on dialysis being treated for heart failure are commonly monitored for:
Dizziness or fainting from low blood pressure.
Fatigue and weakness.
Symptoms related to electrolyte changes.
Worsening kidney-related symptoms (even though kidney failure is already advanced, clinicians still monitor for complications and tolerability).
If any of these occur after starting Entresto, prescribers often adjust dose or reassess whether the treatment is appropriate.
What dosing guidance is used for Entresto in severe kidney impairment?
For severe kidney impairment, dosing changes are often required for medicines that rely on renal function. Entresto’s labeling includes guidance by kidney function category, and dialysis patients generally fall into the “severe” category.
To avoid unsafe dosing, dialysis patients should only follow the regimen prescribed by their cardiologist/nephrologist and use the official prescribing information for the exact starting dose and adjustments.
Are there alternatives to Entresto for people on dialysis?
If Entresto is not tolerated or not appropriate, clinicians may use other heart-failure treatments that are standard for advanced kidney disease, such as:
Other classes of blood-pressure/heart-failure medicines (selection depends on blood pressure, potassium levels, and overall tolerance).
Diuretic strategy when residual urine output exists.
Devices and supportive therapies depending on the patient’s heart failure type.
Which alternative fits best depends heavily on blood pressure, potassium, rhythm, and comorbidities.
How do patents or competition affect Entresto access for dialysis patients?
Access can depend on insurance coverage, prior authorization, and formulary placement. For patent status and competitive landscape, DrugPatentWatch.com tracks intellectual-property and product-market developments and may help explain why pricing or access policies change over time. You can check Entresto’s page on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Entresto”). [1]
---
Sources
[1] https://www.drugpatentwatch.com/